1,1-Bis (3′-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model  by Andey, Terrick et al.
European Journal of Pharmaceutical Sciences 50 (2013) 227–241Contents lists available at ScienceDirect
European Journal of Pharmaceutical Sciences
journal homepage: www.elsevier .com/ locate/e jps1,1-Bis (30-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit
lung cancer cell and tumor growth in a metastasis model0928-0987  2013 The Authors. Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.ejps.2013.07.007
⇑ Corresponding author. Address: Department of Pharmaceutics, Florida A&M
University, 1520 South Martin Luther King Jr. Blvd., Dyson Pharmacy Bldg. Room
021, Tallahassee, FL 32307, USA. Tel.: +1 850 345 2754; fax: +1 850 599 3813.
E-mail address: mandip.sachdeva@famu.edu (M. Singh).
Open access under CC BY-NC-ND license.Terrick Andey a, Apurva Patel a, Tanise Jackson a, Stephen Safe b, Mandip Singh a,⇑
aDepartment of Pharmaceutics, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, 1520 South Martin Luther King Jr. Blvd., Tallahassee, FL 32307, USA
bDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX, USA
a r t i c l e i n f o a b s t r a c tArticle history:
Received 15 March 2013
Received in revised form 23 June 2013
Accepted 15 July 2013
Available online 23 July 2013
Keywords:
Nur77/TR3
Metastatic
Nebulizer
Angiogenesis
Inhalation1,1-Bis(3-indolyl)-1-(p-substitutedphenyl)methane (C-DIM) compounds exhibit remarkable antitumor
activity with low toxicity in various cancer cells including lung tumors. Two C-DIM analogs, DIM-C-pPh-
OCH3 (C-DIM-5) and DIM-C-pPhOH (C-DIM-8) while acting differentially on the orphan nuclear receptor,
TR3/Nur77 inhibited cell cycle progression from G0/G1 to S-phase and induced apoptosis in A549 cells.
Combinations of docetaxel (doc) with C-DIM-5 or C-DIM-8 showed synergistic anticancer activity
in vitro and these results were consistent with their enhanced antitumor activities invivo. Respirable
aqueous formulations of C-DIM-5 (mass median aerodynamic diameter of 1.92 ± 0.22 lm and geometric
standard deviation of 2.31 ± 0.12) and C-DIM-8 (mass median aerodynamic diameter of 1.84 ± 0.31 lm
and geometric standard deviation of 2.11 ± 0.15) were successfully delivered by inhalation to athymic
nude mice bearing A549 cells as metastatic tumors. This resulted in signiﬁcant (p < 0.05) lung tumor
regression and an overall reduction in tumor burden. Analysis of lung tumors from mice treated with
inhalational formulations of C-DIM-5 and C-DIM-8 showed decreased mRNA and protein expression of
mediators of tumor initiation, metastasis, and angiogenesis including MMP2, MMP9, c-Myc, b-catenin,
c-Met, c-Myc, and EGFR. Microvessel density assessment of lung tissue sections showed signiﬁcant
reduction (p < 0.05) in angiogenesis and metastasis as evidenced by decreased distribution of immuno-
histochemical staining of VEGF, and CD31. Our studies demonstrate both C-DIM-5 and C-DIM-8 have
similar anticancer proﬁles in treating metastatic lung cancer and possibly work as TR3 inactivators.
 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Studies have underscored the anticancer and/or antitumor
activities of 3,30-diindolylmethane (DIM), a metabolite of the natu-
rally-occurring indole-3-carbinol (I3C) found in cruciferous vegeta-
bles such as broccoli (Chen et al., 2012; Shorey et al., 2012). The
anticancer activity of DIM has been investigated in various cell
lines including prostate, breast, and colon (Abdelbaqi et al., 2011;
Chen et al., 2012; Lerner et al., 2012). Further, DIM has been shown
to induce cell cycle arrest and apoptosis in HCT-116, SW480, and
HT-29 colon cancer cells (Choi et al., 2009; Lerner et al., 2012).
1,1-Bis(30-indolyl)-1-(p-substitutedphenyl)methanes (C-DIMs) are
synthetic analogs of DIM that exhibit structure-dependent
activation of peroxisome proliferator-activated receptor gamma(PPAR-c) receptor (p-triﬂuoro, p-tert-butyl, p-cyano, and p-phenyl
analogs), and the orphan receptor Nur77/TR3 (unsubstituted and
p-methoxy analogs) (Cho et al., 2010, 2008, 2007; Guo et al.,
2010; Ichite et al., 2009; Lee et al., 2009; Lei et al., 2008a, 2008b;
Safe et al., 2008; Yoon et al., 2011). In addition, the 1,1-Bis(30-indo-
lyl)-1-(p-hydroxyphenyl)methane analog (DIM-C-pPhOH) deacti-
vates TR3 (Lee et al., 2011a, 2010). Nur77/TR3 (NR4A1) is a
member of the NR4A family of receptors which also include Nurr1
(NR4A2) and Nor1 (NR4A3). These orphan nuclear receptors were
initially identiﬁed as intermediate-early genes induced by nerve
growth factor in PC12 cells (Milbrandt, 1988). Endogenous ligands
for NR4A receptors have not been identiﬁed and these receptors
are widely distributed in many organs including skeletal muscles,
heart, liver, kidney and brain where they modulate various physi-
ological and pathological processes (Maxwell and Muscat, 2006;
McMorrow and Murphy, 2011; Safe et al., 2011). TR3 is a pro-onco-
genic factor in various cancer cells where knockdown of TR3 re-
sults in cell growth inhibition, induction of apoptosis, and
decreased angiogenesis (Kolluri et al., 2003; Lee et al., 2011a,
2010; Safe et al., 2011; Wu et al., 2008).
DIM-C-pPhOCH3 (C-DIM-5) and DIM-C-pPhOH (C-DIM-8) have
been recognized as prototypical activators and deactivators of
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et al., 2011; Yoon et al., 2011). C-DIM-5 has been used as a proto-
typical activator of TR3 in transactivation assays using GAL4-TR3/
GAL4-response element reporter gene assay system; however
subsequent studies with GAL4-TR3 (human) showed minimal
transactivation by C-DIM-5. C-DIM-5 induces a nuclear TR3-depen-
dent apoptosis in pancreatic and colon cancer cells (Cho et al., 2007;
Lee et al., 2009). C-DIM-8 blocked the activation of TR3 in pancre-
atic, bladder, and lung cancer cells resulting in growth inhibition
and induction of apoptosis and the results were similar to that
observed after TR3 knockdown by RNAi (Lee et al., 2011b, 2010).
Non-small cell lung cancer (NSCLC) accounts for approximately
9 out of 10 lung cancer cases (Whitehead et al., 2003). Success of
treatment of NSCLC however, is plagued by low efﬁcacy and toxic-
ity of drugs as well as development of tumor resistance. Localized
delivery of aerosolized drugs to the lungs ensures delivery of opti-
mum drug concentrations at target tissue and the enhanced poten-
tial of inhalation drug delivery for lung cancer treatment has been
demonstrated using aerosolized 9-nitrocamptothecin, doxorubicin,
and cisplatin (Wittgen et al., 2007). We hypothesize that inhalation
delivery of the TR3 activator C-DIM-5 and the TR3 deactivator C-
DIM-8 along with intravenous (i.v.) administration of docetaxel
(doc) will provide an enhanced antitumor activity in NSCLC. In this
study, we investigated the feasibility of aerosolizing C-DIM-5 and
C-DIM-8 for evaluating their anticancer activities alone and in
combination with doc in a metastatic mouse lung tumor model.
2. Materials and methods
2.1. Cell lines and reagents
C-DIM-5 and C-DIM-8 were synthesized as described
(Chintharlapalli et al., 2005). The Mouse Cancer PathwayFinder
RT2 Proﬁler™ PCR Array was from SABiosciences (Valencia, CA)
and Trizol reagent was from Invitrogen (Carlsbad, CA). BCA Protein
Assay Reagent Kit was procured from Pierce (Rockford, IL). TR3, b-
actin, MMP2, MMP9, rabbit anti-mouse antibody and secondary
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA.).
CD31, VEGFR2, p21, survivin, PARP, cleaved-PARP, cleaved
caspase3, cleaved caspase8, Bcl2, and NFk-b, b-catenin, c-Met, c-
Myc, and EGFR primary antibodies were purchased from Cell
Signaling Technology (Danvers, MA). A549 cell line was obtained
from American Type Culture Collection (Manassas, VA, USA).
A549 cells were maintained in F12K medium supplemented with
10% FBS and penicillin/streptomycin/neomycin at 37 C in the
presence of 5% CO2 under a humidiﬁed atmosphere. The cell line
throughout culture and during the duration of the study was peri-
odically tested for the presence of mycoplasma by polymerase
chain reaction (PCR). Cells used for the study were between 5
and 20 passages. All other chemicals were of either reagent or tis-
sue culture grade.
2.2. In-vitro cytotoxicity against A549 cells
The in vitro cytotoxicity of C-DIM-5 and C-DIM-8 alone and in
combination with docwas evaluated in A549 cell line as previously
reported (Chougule et al., 2011; Patlolla et al., 2010). A549
(104 cells/well) cells was seeded in 96-well plates and incubated
at 37 C for 24 h. The cells were treated with concentrations of
doc, C-DIM-5, C-DIM-8 or DMSO. The effects of doc in combination
with C-DIM-5 or C-DIM-8 were also carried out and cell viability in
each treatment group was determined at the end of 24 h by the
crystal violet dye assay (Ichite et al., 2009). The interactions
between doc and C-DIM-5 or C-DIM-8 were evaluated by isobolo-
graphic analysis by estimating the combination index (CI) as
described (Luszczki and Florek-Łuszczki, 2012). Hence, a CI > 1indicates antagonism; CI = 1 indicates additive effect; and a CI < 1
indicates synergism.
2.3. In vitro detection of apoptosis in A549 cells
The acridine orange-ethidium bromide (AO/EB) staining meth-
od was used to investigate induction of apoptosis in A549 cells.
The procedure as previously described (Ribble et al., 2005) in-
volved seeding of A549 cells (104 cells/well) in a 96-well plate fol-
lowed by a 24-h recovery at 37 C. Treatment consisted of DMSO,
C-DIM-5 (10 lM, 20 lM), C-DIM-8 (10 lM, 20 lM), doc (10 nM),
C-DIM-5 (10 lM, 20 lM) + doc (5 nM), and C-DIM-8 (10 lM,
20 lM) + doc (5 nM). After 48 h cells were washed twice with
PBS, permeabilized with 100 ll pre-chilled PBS and stained with
8 ll of staining solution (i.e. ethidium bromide [100 lg/ml] + acri-
dine orange [100 lg/ml] in PBS). The cells were viewed under an
Olympus BX40 ﬂuorescence microscope connected to a DP71 cam-
era (Olympus, Japan). Apoptotic cells were quantiﬁed and the
results presented as means of percentage apoptotic cells ± SD
normalized against control.
2.4. In vitro cytotoxicity of aerosolized C-DIM-5 and C-DIM-8
The in vitro efﬁcacies of the aerosolized C-DIM formulations
were evaluated in A549 cells using a six-stage viable impactor con-
nected to the Pari LC Star jet nebulizer and operated for 5 min at a
ﬂow rate of 28.3 l/min. A549 cells (106 cells in 15 ml of medium)
were seeded in sterile petri dishes (Graseby Andersen, Smyrna,
GA) and placed on stage 1 through stage 6 of the viable impactor.
A549 cells were exposed to nebulized C-DIM-5 and C-DIM-8 for
2 min. The petri dishes were then incubated at 37 C for 72 h under
aseptic conditions. Untreated cells were used as a control. Cells
were washed with PBS and detached from the petri dish using
trypsin. Cells were pelleted by centrifugation at 5000g for 5 min
and resuspended in media. Cell viability was determined by the
trypan blue method (Zhang et al., 2011).
2.5. Fluorescence activated cell sorting (FACS) analysis
Fluorescence activated cell sorting (FACS) analysis of cell cycle
dynamics was carried out as previously described (Li et al.,
2012). A549 cells (104 cells/well) suspended in F12K growth media
were seeded in a 96-well plate format. Treatment consisted of
DMSO, C-DIM-5 (10 lM, 20 lM), or C-DIM-8 (10 lM, 20 lM) and
incubation at 37 C for 24 h. Cells were harvested using 0.25% tryp-
sin and centrifuged for 5 min at 5000g. Cells were washed in 5 ml
of PBS containing 0.1% glucose. Cells were then resuspended in
200 ll of PBS, followed by permeabilization and ﬁxation by drop
wise addition of 5 ml pre-chilled ethanol (70%) and kept at 4 C
for 1 h. Cells were pelleted and washed with 10 ml PBS. The cell
suspension was incubated in 300 ll staining solution comprising
of 1 mg/ml propidium iodide (PI) and 10 mg/ml RNAse A (Sigma
Aldrich, St. Louis, MO). Cells were incubated at 37 C for 1 h and
analyzed by FACS using the BD FACSCALIBUR.
2.6. CaCo2 permeability assays
CaCo2 cells were grown in DMEM media fortiﬁed with 10% fetal
bovine serum, 1% non-essential amino acids, 10 mM HEPES, and a
penicillin/streptomycin/neomycin cocktail in 75 cc ﬂasks. Cells
were maintained under conditions of 5% CO2 and 95% humidity
at 37 C. Sub-coﬂuent CaCO2 monolayers were washed with
Dulbecco’s phosphate-buffred saline (DPBS) 2 and detached with
trypsin-EDTA (0.25%) and seeded (5.0  104) in a 0.5 ml-volume
into the apical chamber (with 1.5 ml of cell-free media in the baso-
lateral chamber) of a Costar collagen-coated PTFE membrane
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tained by media replacement in both chambers every other day for
14 days, and subsequently, daily for up to 21 days. The integrity of
the monolayer formed was assessed by trans-epithelial electrical
resistance (TEER) readings employing a Millicell (MilliPore,
Bedford, MA). Monolayers registering net TEER values ranging
between 400 and 500X were used for permeation assay. Before
the permeation study, CaCO2 monolayer integrity and permeability
were assessed using the Millicell and Lucifer yellow respectively.
Permeation was carried out with 10 lg/ml (0.5 ml) of C-DIM-5 or
C-DIM-8 (in pH-adjusted HBSS-HEPES buffer) and 1.5 ml of blank
HBSS-HEPES buffer (pH 7.4) added to the apical and basolateral
compartments respectively. The transwells were perfused with
5% CO2 in a humidiﬁed 37 C atmosphere under constant stirring
at 50 rpm. Collection of permeated samples (200 ll) from the baso-
lateral compartments were done at 2 h. The samples were injected
into a Symmetry C18 column of an HPLC under an isocratic ﬂow ofFig. 1. C-DIM-5 and C-DIM-8 alone and in combination with docetaxel (doc) inhibit cell g
treated with C-DIM-5, C-DIM-8 or DMSO for 24 and cell viability was determined by cryst
treatment group and the data are presented as means with SD (n = 3 per group). *P < 0.0
(E and F) Cytotoxicity of nebulized C-DIM-5 and C-DIM-8 in A549 cells. Cells (1  106)
C-DIM-5 and C-DIM-8 for 2 min and viability determined by the trypan blue exclusion
viability of treatment normalized against the control treatment (nebulizer solution). Ex1 ml/min in an acetonitrile:water (70:30) mobile phase and detec-
tion done at a wavelength of 240 nm. Apparent permeability
(Papp) was computed thus:
Papp ¼ ðð½C  VbÞ=ð½Ca VaÞÞ=ðT  Va=AÞ
where [C] = drug concentration in acceptor compartment; Vb = vol-
ume of ﬂuid in acceptor compartment; [C]a = drug concentration in
donor compartment; Va = volume of ﬂuid in donor compartment;
T = time; and A = surface area of transwell membrane.
2.7. Formulation and aerodynamic characterization of nebulizer
solution
Aqueous formulations suitable for nebulization were prepared
by dissolving C-DIM-5 (50 mg) in 0.5 ml ethanol and 500 mg of vita-
min E TPGS and diluting up to 10 ml with distilled water to obtain a
5 mg/ml solution of C-DIM-5. This was used for in vitro cytotoxicityrowth and induce apoptosis in NSCLC. (A–D) A549, LnCap, PC3, and H460 cells were
al violet staining. The experiment was repeated three times with three replicates per
5 versus control and **P < 0.05 versus C-DIM-5, C-DIM-8 and doc single treatments.
were seeded in sterile petri plates in 15 ml of F12K media, exposed to aerosolized
as described in materials and methods. Results are presented as percentage cell
periments were done in triplicates and repeated 3 times.
Fig. 2. (A and B) Induction of apoptosis by C-DIM-5, C-DIM-8, doc and their combinations. Cells were treated with (i, ii) DMSO, (iii, iv) doc (10 nM), (v, vi) C-DIM-5 (10 lM),
(vii, viii) C-DIM-8 (10 lM), (ix, x) C-DIM-5 (10 lM) + doc (5 nM), (xi, xii) C-DIM-8 (10 lM) + doc (5 nM), (xiii, xiv) C-DIM-5 (20 lM), (xv, xvi) C-DIM-8 (20 lM), (xvii, xviii)
C-DIM-5 (20 lM) + doc (5 nM), and (xix, xx) C-DIM-8 (20 lM) + doc 5 nM, incubated at 37 C for 24 h and apoptosis was determined by acridine orange-ethidium bromide
staining as described in materials and method. Experiments were done in triplicates and repeated 3 times. *P < 0.05 versus control and **P < 0.05 versus C-DIM-5, C-DIM-8 and
doc single treatments. (C) C-DIM-5 and C-DIM-8 cause cell cycle arrest. Cells were treated with DMSO, C-DIM-5 (10 lM), C-DIM-8 (10 lM), C-DIM-5 (20 lM) and C-DIM-8
(20 lM) respectively, then harvested, ﬁxed, stained and analyzed by FACS as described in materials and methods. Data are presented as means of events with SD of 3
experiments (*P < 0.05 vs DMSO).
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solution was prepared and used for animal studies and comparableformulations of C-DIM-8 were also prepared. An eight-stage Ander-
son cascade impactor (ACI),Mark IIwas used for particle size assess-
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solution to mitigate particle rebound. The formulation was nebu-
lized using a PARI LC STAR jet nebulizer at a dry compressed air ﬂow
rate of 4 l/min for 5 min into the cascade impactor at a ﬂow rate of
28.3 l/min. Aerosol particles deposited along the ACI (throat, jet
stage, plates on impactor stages 0–7, and ﬁlter) were collected by
washing with 5 ml of mobile phase comprising acetonitrile:water
(70:30) and analyzed by high performance liquid chromatography
(HPLC). The analysis was performed on aWaters HPLC system using
a SymmetryC18 column (5 lm,4.6  250 mm)with aNova-PackC8
guard column at a wavelength of 240 nm and ﬂow rate of 1 ml/min.
The mass median aerodynamic diameter (MMAD) and geometric
standard deviation (GSD) were computed from the obtained impac-
tor data utilizing a validated protocol (Patlolla et al., 2010). Aerody-
namic analyses of the samples were determined in triplicate and
data presented as means with SD.
2.8. In vivo metastatic lung tumor model
All experiments involving animals were reviewed and approved
by the Animal Care and Use Committee (ACUC) of Florida A&M
University. Female Nu/Nu mice weighing 20–25 g (Charles River
Laboratories) were utilized for determining anticancer activities.
The animals were acclimated to laboratory conditions for 1 week
prior to experiments and were maintained on standard animal
chow and water ad libitum. The room temperature was maintained
at 22 ± 1 C and the relative humidity of the experimentation room
was kept in the range of 35–50%. For nebulization studies, 4 daysFig. 3. In vitro permeability of (A) C-DIM-5 and (B) C-DIM-8 across CaCO2
monolayer. Cells were maintained on collagen-coated transwells for 21 days and
permeation studies performed as described under materials and methods. Both
compounds show poor permeabilities under acidic and alkaline conditions with
C-DIM-8 exhibiting a pH-dependent increase at high pH. Data were analyzed by
GraphPad Prism and represented as the means with SD of 3 experiments. Signiﬁcant
differences (*P < 0.05 vs acidic pH) are indicated.prior to the start of experiment, animals were trained using nebu-
lized water for 30 min to acclimatize them to the nebulizing envi-
ronment and prevent any discomfort during the administration of
the drug formulations. To induce tumor growth in the lungs, single
cell suspensions of A549 cells were harvested from subconﬂuent
cell monolayers. These were suspended in a ﬁnal volume of
100 ll PBS and inoculated into female athymic nude mice
(2  106 cells per mouse) by tail vein injection to induce pulmon-
ary metastasis. The animals were randomized into six (6) groups
24 h post injection and kept for 14 days before tumor growth in
lungs. The metastatic tumor model was validated previously for
consistency in tumor induction and incidence using 1  106 (group
1), 2  106 (group 2), and 3  106 (group 3) cells per mouse (n = 6).
The protocol for group 2 was adopted for the study since it satisﬁed
the requirements of tumor induction and survival of animals with-
in the experimental period of 6 weeks. The tumor incidence was
consistent across all animals with statistically insigniﬁcant vari-
ability in tumor volume, weight and nodule (p < 0.05).Fig. 4. In vitro characterization of aerosolized C-DIM-5 and C-DIM-8 emulsiﬁed
with D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS). (A and B) Aerosol
droplet size distribution. C-DIM-5 and C-DIM-8 were emulsiﬁed with TPGS (5 mg/
ml) and nebulized for 5 min and the concentration of C-DIM determined by HPLC as
described in materials and methods. Data were analyzed by GraphPad Prism and
represented as the means with SD of 3 experiments. Signiﬁcant (*P < 0.05 vs
unnebulized formulation) differences are indicated.
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Mice were held in SoftRestraint™ (SCIREQ Scientiﬁc Respiratory
Equipment Inc, Montreal, QC) attached to an inExpose™ (SCIREQ)
nose-only inhalation tower and exposed to the aerosolized drug
for 30 min. Treatment consisted of 8 animals in each group which
were (i) control group (nebulized vehicle), (ii) Group II (5 mg/ml of
nebulized C-DIM-5), (iii) Group III (5 mg/ml of nebulized C-DIM-8),
(iv) Group IV (5 mg/ml of nebulized C-DIM-5 + 10 mg/kg/day of doc
i.v.), (v) Group V (5 mg/ml of nebulized C-DIM-8 + 10 mg/kg/day of
doc i.v.), and (vi) Group VI (10 mg/kg/day of doc i.v. 2/week).
Treatment was continued for 4 weeks on alternate days and
weights were recorded 2/week. On day 42, all animals were
euthanized by exposure to isoﬂurane. Mice were then dissected
and lungs, heart, liver, kidneys, and spleen were removed and
washed in sterile PBS. Lung weights, tumor weights and volume
were estimated. Organs were removed, and either ﬁxed in 10% for-
malin and embedded in parafﬁn or snap-frozen in liquid nitrogen
and stored at 80 C. Histologic sections were made from lung tis-
sues and stained with hematoxylin and eosin (H&E) for further
analysis. Where applicable, doc indicates treatment of mice by
intravenous (i.v.) injection of docetaxel by tail vein injectionFig. 5. Regression analysis of lung tumor. Mice were randomized into 6 groups (n = 8 per
aerosol (30 min exposure of 5 mg/ml), (iv) C-DIM-8 aerosol (30 min exposure of 5 mg/m
C-DIM-8 aerosol (30 min exposure of 5 mg/ml) + i.v. doc (10 mg/kg/day). (A) Lung tumo
weights were recorded 2 a week and results were presented as means of body weight
described under materials and methods. (D) Mice lung were weighed following resection
with SD (n = 8 per group). The differences in lung weight were not determined to be sig2/week, C-DIM-5 and C-DIM-8 indicate 30 min exposure of mice
to 5 mg/ml nebulization on alternate days respectively. C-DIM-
5 + doc and C-DIM-8 + doc indicate 30 min exposure of mice to
5 mg/ml nebulized C-DIM-5 and C-DIM-8 on alternate days respec-
tively plus intravenous injection of doc 2/week.2.10. Total deposited dose
The estimated total deposited amount of inhaled drug (D) for
the ambient air was calculated by the following formula:
D ¼ CC-DIM  V  DI T;
where CC-DIM = concentration of C-DIM in aerosol volume (C-DIM-5;
48.9 lg/l, C-DIM-8; 51.6 lg/l) estimated as the amount of C-DIM re-
ceived from each port of the inhalation assembly. V = volume of air
inspired by the animal during 1 min (1.0 l min/kg); DI = estimated
deposition index (0.3 for mice), and T = duration of treatment in
min (30 min). Under these conditions, the total deposited dose of
aerosol formulations of C-DIM-5 and C-DIM-8 were 0.440 mg/kg/
day and 0.464 mg/kg/day respectively.group) and treated for 4 weeks with (i) vehicle, (ii) doc (10 mg/kg/day), (iii) C-DIM-5
l), (v) C-DIM-5 aerosol (30 min exposure of 5 mg/ml) + i.v. doc (10 mg/kg/day), (vi)
r morphology was determined as described in the material and methods. (B) Body
with SD (n = 8 per group). (C) Lung pathology was investigated by H&E staining as
to determine changes due to toxicity or pathology. Data were presented as means
niﬁcant (NS = not signiﬁcant).
Fig. 6. Tumor regression analysis. (A) Mean tumor weights and (B) volumes were
determined as described in the materials and methods. Tumor volumes were
calculated using the formula Volume = ((width)2  (length))  0.5. Results are
presented as means of tumor volume with SD (n = 8 per group). One-way ANOVA
followed by Dunnett’s test was used to compare differences observed between
control and treatment groups and Turkey’s test was used to compare differences
between combination and single treatment groups. Signiﬁcant (*P < 0.05 vs control
and **P < 0.05 vs C-DIM-5, C-DIM-8 and doc single treatments) differences are
indicated.
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Tissue homogenates from excised lung tumor were lysed on ice
using RIPA buffer (G-Biosciences, St. Louis, MO). Total protein con-
tent was determined by the BCA method of protein estimation
according to manufacturer’s protocol. The protein samples
(50 lg) were separated on a Mini-PROTEAN TGX™ gel (Bio-Rad,
Hercules CA) and blotted onto nitrocellulose membranes as previ-
ously described (Ichite et al., 2010). The blots were then probed
with primary antibodies targeting cleaved caspase8, cleaved cas-
pase3, PARP, cleaved PARP, survivin, NfkB, p21, Bcl2, TR3 and b-ac-
tin (as loading control). Following incubation of membranes with
HRP-conjugated secondary antibodies, chemiluminescent signal
detection of proteins of interest was aided by autoradiography fol-
lowing exposure to SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Fisher Scientiﬁc Inc, Rockford, IL). Blots were
quantiﬁed by densitometry with the aid of ImageJ (rsb-
web.nih.gov/ij/) and the results presented as means of protein/b-
actin ratio with SD.
2.12. Mouse cancer pathwayﬁnder PCR array
Total RNA from lung tissue homogenate was extracted using
Trizol reagent per manufacturer’s protocol (Invitrogen, Carlsbad
CA) and converted to complementary DNA using SABiosciences’
RT2 First Strand Kit. The gene expression of a panel of 84 genes rep-
resenting six biological pathways implicated in transformation and
tumorigenesis was proﬁled using the Mouse Cancer PathwayFinder
RT2 Proﬁler™ PCR Array. The array included ﬁve controls including
GAPDH and b-actin as housekeeping genes. Ampliﬁcation was per-
formed on an ABI 7300 RT-PCR and data analysis done with a PCR
Array Data Analysis Software (SA Biosciences, Valencia CA).
2.13. Terminal deoxynucleotidyl transferase-mediated dUTP nick-End
labeling (TUNEL) assay
Apoptosis detection on parafﬁn-embedded the lung sections
was carried out using the DeadEnd™ Colorimetric Apoptosis
Detection System (Promega, Madison, WI) following the manufac-
turer’s protocol. Micrographs of the stained sections (40) were
obtained with the aid of an Olympus BX40 ﬂuorescence micro-
scope connected to a DP71 camera (Olympus, Japan) with a DP
controller and DP manager software. Quantiﬁcation of apoptotic
cells was done using Image J software (NIH, Bethesda MD).
2.14. Immunohistochemistry for VEGF and TR3 expression
Formalin-ﬁxed, parafﬁn-embedded lung sections mounted on
slides were deparafﬁnized with xylene and dehydrated through
graded concentrations of alcohol, and then incubated with 3%
hydrogen peroxidase for 20 min to block endogenous peroxidase
activity. Following antigen retrieval for VEGF, the sections were
incubated overnight at 4 C with primary antibody for VEGF conse-
quent to incubation with biotinylated secondary antibody,
followed by streptavidin. Following addition of substrate-chromo-
gen and counterstaining with hematoxylin, VEGF expression were
identiﬁed by the brown cytoplasmic staining. Immunostaining for
TR3 was carried out following the same protocol using primary
antibody for TR3 (Santa Cruz Biotechnology, Santa Cruz CA). Estab-
lished (VEGF or TR3) immunoreactive lung tissue sections and
primary antibody-null sections were included as positive and neg-
ative controls respectively. Areas showing immunoreactivity for
VEGF or TR3 coupled with evidence of tissue remodeling as
evidence of tumor growth were selected; and ﬁve random ﬁelds
(under a combined magniﬁcation of 400) were selected for scor-
ing. Scoring of VEGF or TR3 immunopositivity was carried out bycalculating the immunohistochemical score (IHS) as the sum of
the quantity and staining intensity scores as demonstrated by
Saponaro et al. (2013). Here, the quantity score (percentage immu-
nopositive cells; 0 = immunonegative, 1 = 25% immunopositive
cells, 2 = 26–50% immunopositive cells, 3 = 51–75% immunoposi-
tive cells, and 4 = 76–100% immunopositive cells) and staining
intensity score (0 = no intensity, 1 = weak intensity, 2 = moderate
intensity, and 3 = strong intensity) were combine to give a mini-
mum-to-maximum IHS of 0–7. Scoring was done by two research-
ers independently at three different times and the data collated
and the mean IHS computed. Staining for each marker was done
in triplicates and the experiments were repeated three times.2.15. Assessment of microvessel density
Tissue sections (4–5 lm thick) mounted on poly-L-lysine–
coated slide were deparafﬁnized and blocked for peroxidase activ-
ity. After washing with PBS, the sections were pretreated in citrate
buffer in a microwave oven for 20 min at 92–98 C. After washing
(2) with PBS, specimens were incubated in 10% normal goat ser-
um for 20 min. Subsequently, the sections were incubated with a
1:500 diluted mouse CD31 monoclonal antibody at room temper-
ature for 1 h, followed by a 30 min treatment with rabbit anti-
mouse antibody. After washing (3) with PBS, the section was
developed with diaminobenzidene-hydrogen peroxidase substrate,
and counterstained with hematoxylin. To calculate microvessel
density (MVD), three most vascularised areas of the tumor (‘hot
spots’) were selected and mean values obtained by counting
vessels. A single microvessel was deﬁned as a discrete cluster of
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ence of a lumen. Microvessel counts were performed at 400 (40
objective lens and 10 ocular lens; 0.74 mm2 per ﬁeld). Tumors
with <200 microvessels/mm2 were assigned a low microvessel
density, whereas those with >200 microvessels/mm2 were as-
signed a high microvessel density (Couvelard et al., 2005).
2.16. Statistics
One-way ANOVA followed by Dunnett’s and Tukey’s Multiple
Comparison Tests were performed to determine the signiﬁcance
of differences between control and all treatment groups and
among groups respectively using GraphPad PRISM version 5.0. Dif-
ferences were considered signiﬁcant in all experiments at p < 0.05
(*, signiﬁcantly different from untreated controls; **, signiﬁcantly
different from C-DIM-5 and C-DIM-8 and doc single treatments
unless otherwise stated).
3. Results
3.1. C-DIM-5 and C-DIM-8 inhibit growth of A549 cells
C-DIM-5 and C-DIM-8 were signiﬁcantly cytotoxic (p < 0.05) to
A549 cells with 24 h IC50 values of 14.29 ± 2.30 lM andFig. 7. Histology of lung sections from metastatic lung tumors. Mice from the various tre
as described in materials and methods. Results are presented as percentage VEGF-positi
replicate treatments for each group (n = 3 per group) and presented as means ± SD. One
between control and treatment groups and Turkey’s test was used to compare difference
and p < 0.05 vs C-DIM-5, C-DIM-8 and doc single treatments) differences are indicated16.18 ± 1.59 lM respectively (Fig. 1A and B). The broad spectrum
of cytotoxic activities of the C-DIM compounds was also evident
in LnCap, PC3, and H460 cell lines (Fig. 1C and D). Interaction of
C-DIM-5 and C-DIM-8 with doc inhibited A549 cell growth expo-
nentially with CI values of 0.46 ± 0.027 and 0.51 ± 0.031 (i.e. syner-
gistic) respectively. Deposition on stages 3, 4, 5 and 6 were
selected, representative of the respirable mass and used in the
assessment of cytotoxicity (Fig. 1E and F). Cell survival on stage 5
of the viable impactor signiﬁcantly decreased to 17.75% and
17.10% (p < 0.05) after treatment with nebulized C-DIM-5 and C-
DIM-8 respectively.
3.2. C-DIM-5 and C-DIM-8 induce apoptosis and cause Go/G1-phase to
S-phase arrest in A549 cells
Representative ﬂuorescence micrographs of acridine orange-
ethidium bromide-stained cells revealed the percentages of cells
undergoing apoptosis (Fig. 2A). This was after treatment with
DMSO, doc (10 nM), C-DIM-5 (10 lM), C-DIM-5 (10 lM) + doc
(5 nM), C-DIM-8 (10 lM), C-DIM-8 (10 lM) + doc (5 nM),
C-DIM-5 (20 lM), C-DIM-5 (20 lM) + doc (5 nM), C-DIM-8
(20 lM), and C-DIM-8 (20 lM) + doc (5 nM) (Fig. 2A). There
was evidence of induction of early and late apoptosis by doc
(10 nM) [11.5 ± 1.00%], C-DIM-5 (10 lM) [20.5 ± 1.85%], andatment groups (see Fig. 5) were stained and quantitated for (A, B) VEGF, (C, D) CD31
ve cells (B) and average microvessel density (D) of control (set at 100%). Results are
-way ANOVA followed by Dunnett’s test was used to compare differences observed
s between combination and single treatment groups. Signiﬁcant (p < 0.05 vs control
.
Fig. 8. Histology of lung sections from metastatic lung tumors. (A) TdT-mediated dUTP Nick-End Labeling was performed on tumor sections from mice from the various
treatment groups (see Fig. 5). (B) Staining were quantitated and presented as percentage of apoptotic cells normalized against control. (C) Immunohistochemical staining for
TR3 expression following treatment as above were scored and presented as means of IHC score (D). Results are replicate treatments for each group (n = 3 per group) and
presented as means ± SD One-way ANOVA followed by Dunnett’s test was used to compare differences observed between control and treatment groups and Turkey’s test was
used to compare differences between combination and single treatment groups. Signiﬁcant (p < 0.05 vs control) differences are indicated.
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when C-DIM-5 and C-DIM-8 where combined with doc [C-
DIM-5 (10 lM) + doc (5 nM), 30 ± 2.90%; C-DIM-8 (10 lM) + doc
(5 nM), 34 ± 3.60%] (Fig. 2B). The number of apoptotic cells sig-
niﬁcantly increased (p < 0.05) at higher concentrations (20 lM)
of C-DIM-5 [24 ± 1.80%] and C-DIM-8 [25.5 ± 2.40%]. This was
further enhanced when 20 lM C-DIM-5 and C-DIM-8 were co-
treated with 5 nM doc [40 ± 3.45%, and 41 ± 3.60% respectively]
(Fig. 2B).
Treatment of A549 cells with DMSO resulted in accumulation of
72.34 ± 0.51% of cells in G1, 3.20 ± 0.13% in G2 and 24.58 ± 0.49% of
cells in S-phase (Fig. 2C). However, after treatment with 10 lM
C-DIM-5, 76.98 ± 0.51% of cells accumulated in G1, 1.20 ± 0.21% in
G2 and 21.82 ± 0.52% in S-phase. Treatment with C-DIM-5
(20 lM) increased cells accumulating in G1 to 82.46 ± 0.95%,
2.25 ± 0.31% in G2 and decreased cells in S-phase 15.29 ± 0.64%
(Fig. 2C). Treatment of A549 cells with 10 lM C-DIM-8 resulted
in 74.46 ± 0.66%, 2.15 ± 0.35%, and 23.39 ± 0.75% of cells accumu-
lating in G1, G2, and in S-phase respectively, whereas at 20 lM,
C-DIM-8 arrested 81.66 ± 0.22% cells in G1, 2.21 ± 0.44% in G2,
and 16.13 ± 0.29% in S-phase (Fig. 2C).3.3. CaCO2 permeability assays
The apparent permeability (Papp) of C-DIM-5 and C-DIM-8
under acidic conditions (pH 5.0 and pH 6.0) was investigated as a
basis for their oral delivery (Fig. 3). At pH of 5.0 and 6.0 the Papp
of C-DIM-5 was 1.12  107 cm/s and 1.11  107 cm/s respec-
tively (Fig. 3A). The Papp of C-DIM-8 increased from
1.0712  107 cm/s at pH 5.0–1.11  107 cm/s at pH 6.0
(Fig. 3B). While there was no difference between the two Papp of
C-DIM-5, the differences in the Papp of C-DIM-8 were not consid-
ered signiﬁcant (p > 0.05). The Papp of C-DIM-5 did not change sig-
niﬁcantly at either pH of 7.0 or 8.0 (Fig. 3A) while that of C-DIM-8
increased signiﬁcantly (p < 0.05) to 1.15  107 cm/s and
1.16  107 cm/s respectively compared to Papp at pH of 5.0 and
6.0 (Fig. 3B).
3.4. Aerodynamic characterization of nebulized C-DIMs
Assessment of size and shape characteristics of nebulized
C-DIM-5 and C-DIM-8 formulations was done by determining their
mass median aerodynamic diameter (MMAD) and geometric
Fig. 9. PCR Array of modulators of tumor growth, tumor inhibition, apoptosis,
metastasis, and angiogenesis. (A, B) Gene expression proﬁle of resected metastatic
lung tumor. RNA from the various treatment groups (see Fig. 5) was converted to
cDNA and analyzed using a Mouse Cancer PathwayFinder RT2 Proﬁler™ PCR Array
as outlined in the materials and methods. Results are expressed as means ± SD
Signiﬁcant (P < 0.05 vs untreated controls) differences are indicated. Results are
expressed as means ± SD for at least 3 replicate determination for each treatment
group and expressed as percentage of values in control tumors (set at 100%). One-
way ANOVA followed by Dunnett’s test was used to compare differences observed
between control and treatment groups and Turkey’s test was used to compare
differences between combination and single treatment groups. Signiﬁcant differ-
ences (P < 0.05 vs control) are indicated.
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methods. As shown for nebulized C-DIM-5 and C-DIM-8 (Fig. 4A
and B respectively), signiﬁcant deposition of aerosol droplets were
achieved on stages 4 through 6 of the impactor. C-DIM-5 and
C-DIM-8 formulations yielded particles with aerodynamic capabil-
ities for deep pulmonary deposition with MMAD of 1.92 ± 0.22 lm,
GSD of 2.31 ± 0.12 and a MMAD of 1.84 ± 0.31 lm and GSD of
2.11 ± 0.15) respectively.
3.5. C-DIM-5, C-DIM-8 and docetaxel combinations inhibit lung tumor
growth
Representative lungs (Fig. 5A) with tumor nodules (black ar-
rows) are shown for mice treated with nebulizer vehicle as control,nebulized C-DIM-5, C-DIM-8 and their combinations with doc.
Compared to control lungs (12 nodules, Fig. 5A-I), tumor nodules
were decreased after treatment with doc (7 nodules, Fig. 5A-II),
C-DIM-5 (5 nodules, Fig. 5A-III), C-DIM-8 (3 nodules, Fig. 5A-IV),
C-DIM-5 + doc (2 nodules, Fig. 5A-V) and C-DIM-8 + doc (2 nodules,
Fig. 5A-VI). Reduction in tumor nodules in all treatment groups
were considered signiﬁcant compared to control (p < 0.05).
H&E staining of representative lung sections (Fig. 5B) also
showed similar behavior. Evidence of tissue remodeling and migra-
tion are evidenced in control (Fig. 5B-I) by abundant nuclei foci.
However, less pathology is evident in groups treated with doc
(Fig. 5B-II), C-DIM-5 (Fig. 5B-III), C-DIM-8 (Fig. 5B-IV), and more
so in C-DIM-5 (Fig. 5B-V) C-DIM-8 (Fig. 5B-VI) combinations with
doc.
There were no variations in body weight (Fig. 5C) or lung
(Fig. 5D) across all treatment groups compared to the control mice.
There were signiﬁcant differences (p < 0.05) in the tumor weights
from mice treated with doc (48 ± 3.68 mg), C-DIM-5
(48 ± 4.20 mg), C-DIM-8 (50 ± 5.36 mg), C-DIM-5 + doc (46 ±
3.47 mg) and C-DIM-8 + doc (45 ± 5.20 mg) compared to vehicle
(100 ± 6.84 mg) (Fig. 6A). Decreased tumor growth based on vol-
umes was also signiﬁcantly (p < 0.05) decreased in the treated
compared to control mice (Fig. 6B). A relative mean tumor volume
of 150 ± 8.90 mm3 was observed in the control mice, and tumor
volume decreased following treatment with doc (66.67%;
50 ± 4.77 mm3), C-DIM-5 (65.33%; 52 ± 4.80 mm3), C-DIM-8
(62.67%; 56 ± 5.80 mm3), C-DIM-5 + doc (74.67%; 38 ± 4.20 mm3),
and C-DIM-8 + doc (70.67%; 44 ± 3.80 mm3) (Fig. 6B).3.6. C-DIM-5 and C-DIM-8 inhibit VEGF expression in lung tumors
C-DIM-5 and C-DIM-8 nebulized formulations inhibited VEGF
expression in A549 lung tumor when given alone and when com-
bined with doc (Fig. 7A). This was observed as positive (dark
brown) immunohistochemical staining for VEGF on lung sections.
Quantiﬁcation of VEGF-positive cells was represented as percent-
age of the mean normalized against control (Fig. 7B). The results
showed a decrease in VEGF staining following treatment with
doc (68 ± 5.82%; Fig. 7A-II), C-DIM-5 (49 ± 5.30%; Fig. 7A-III),
C-DIM-8 (54 ± 5.83%; Fig. 7A-IV), C-DIM-5 + doc (26 ± 4.25%;
Fig. 7A-V) and C-DIM-8 + doc (28 ± 4.02%; Fig. 7A-VI) compared
to control (Fig. 7A-I). The decrease in VEGF expression was signif-
icant across all treatment groups relative to control and between
the single and combination treatments of the same compounds
(p < 0.05). However, the differences in VEGF expression between
C-DIM-5 and C-DIM-8 and between their combinations were not
signiﬁcant (Fig. 7B).3.7. C-DIM-5 and C-DIM-8 decrease microvessel density in lung
tumors
Microvessel density (MVD) was determined by immunopositive
staining for CD31 (Fig. 7C). Tissue sections stained dark brown for
CD31 with a progressive decrease in staining observed for sections
from the treatment groups compared to the control. MVD assess-
ment of sections showed signiﬁcant reduction (p < 0.05) in MVD
in the groups treated with doc (182 ± 10.28 microvessels/mm2;
Fig. 7C-II and D), C-DIM-5 (164 ± 15.31 microvessels/mm2; Fig. 7
C-III and D), C-DIM-8 (158 ± 10.85 microvessels/mm2; Fig. 7 C-IV
and D), C-DIM-5 + doc (106 ± 9.50 microvessels/mm2; Fig. 7 C-V
and D), and C-DIM-8 + doc (118 ± 11.07 microvessels/mm2;
Fig. 7C-VI and D) compared to 248 ± 25.11 microvessels/mm2 in
the control (Fig. 7C-I and D).
Fig. 10. Western blot studies of modulators of tumor growth, tumor inhibition, apoptosis, metastasis, and angiogenesis. (A) C-DIM-5 and (B) C-DIM-8 modulate gene
products associated with growth, survival and (C, D) metastasis. Tumor lysates from the various treatment groups were analyzed by Western blot as outlined in the materials
and method.
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Treatment-related induction of apoptosis was determined by
TUNEL staining which showed positive staining for DNA fragmen-
tation as dark-brown or reddish staining (Fig. 8A). Compared to the
untreated control group (Fig. 8B), there was signiﬁcantly increased
(p < 0.05) DNA fragmentation in mice treated with doc (38 ± 4.02%),
C-DIM-5 (56 ± 6.20%) and C-DIM-8 (60 ± 5.40%), combination
treatment of C-DIM-5 + doc (78 ± 8.11%) and C-DIM-8 + doc
(80 ± 8.90%).3.9. C-DIM-5 and C-DIM-8 and TR3 expression in lung sections
Positive staining for TR3 was evident as dark-brown staining
(Fig. 8C). The pattern of TR3 expression following immunostain-
ing was similar in intensity and was evident of nuclear localiza-
tion in all groups. TR3 immunopositivity was high and
comparable among all groups (IHS = 5–6) and the differences ob-
served were considered to be statiscally insigniﬁcant (p < 0.05)
(Fig. 8D).3.10. C-DIM-5 and C-DIM-8 inhibit genes involved in tumor initiation
and metastasis
A PCR array containing 84 genes that are involved in various as-
pects of tumor initiation, progression, and metastasis was used to
analyze tumor samples from the various treatment groups (Fig. 9A
and B). Both C-DIM-5 and C-DIM-8 decreased expression of Bcl2,
Ccne1, EGFR, Met, MMP2, MMP9, Myc, NCAM1, PTEN, VEGF A,
VEGF B, and VEGF C mRNAs (Fig. 9A and B). C-DIM-5 also downreg-
ulated expression of ANGPT1, Ccd25a and Birc5 mRNAs (Fig. 9A),
and C-DIM-8 inhibited the levels of ATM (Fig. 9B).
Both C-DIM-5 and C-DIM-8 increased markers of apoptosis
including cleaved PARP while uniquely increasing the expression
of cleaved Caspase8 and cleaved Caspase3 respectively (Fig. 10A
and B). C-DIM-5 also induced the expression of p21, the transcrip-
tional modulator of the tumor suppressor p53 (Fig. 10A). Differen-
tially, nebulized C-DIM-8 alone signiﬁcantly inhibited the
expression of PARP, Bcl2, and Survivin compared to the control
and nebulized C-DIM-5 (p < 0.05) (Fig. 10B). Whilst both C-DIM-5
and C-DIM-8 and their combinations with doc decreased the
expression of b-catenin, MMP9, MMP2, c-Myc, c-Met and EGFR
Fig. 11. Lung tumor lysates from the various treatment groups (see Fig. 10) were analyzed by Western blot for (A) MMP9, (B) c-Myc, (C) MMP-2 and their expression
estimated using the ImageJ software (imagej.nih.gov/ij/download/). Protein expression of targets were normalized against b-actin for at least 3 replicate determination for
each treatment group and the results expressed as percentage of control lysate (set at 100%). One-way ANOVA followed by Dunnett’s test was used to compare differences
observed between control and treatment groups and Turkey’s test was used to compare differences between combination and single treatment groups. Signiﬁcant differences
(*P < 0.05 vs control and **P < 0.05 vs C-DIM-5, C-DIM-8 and doc single treatments) are indicated.
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were signiﬁcant differences between them (Figs. 11 and 12).
C-DIM-8 + doc signiﬁcantly decreased the expression MMP9,
c-Myc, b-catenin compared to C-DIM-5 + doc (p < 0.05) (Figs. 11A,
B and 12A respectively). C-DIM-5 + doc and C-DIM-8 + doc inhib-
ited EGFR expression signiﬁcantly but the differences between
them were not signiﬁcant (Fig. 12C).
4. Discussion
In this study, we investigated the enhanced anti-metastatic and
anticancer activities of C-DIM-5 and C-DIM-8 formulated for inha-
lation delivery. C-DIM-5 and C-DIM-8 act on TR3 as activator and
deactivator respectively (Cho et al., 2007; Lee et al., 2011a). They
are highly lipophilic with nominally low membrane permeability.
These properties preclude the achievement of optimalconcentrations at the tumor microenvironment when adminis-
tered orally. And while the anticancer activities of various C-DIM
analogs have been studied, their abilities to inhibit metastasis ha-
ven’t engendered much interest (Chintharlapalli et al., 2005; Cho
et al., 2010, 2008, 2007). Therefore, we planned to overcome the
barriers to effective therapy in advanced lung cancer by formulat-
ing C-DIM-5 and C-DIM-8 in inhalable forms for local lung delivery
in a metastatic tumor model.
C-DIM-8 and C-DIM-5 are generally non-toxic in normal tissue
at therapeutic concentrations (Chintharlapalli et al., 2005; Cho
et al., 2007; Lee et al., 2010, 2009). However, both compounds
inhibited A549 cell growth when administered alone and acted
in synergism with doc.
The nuclear staining properties of acridine orange and ethidium
bromide were employed in in vitro detection of apoptosis in A549
cells (Ribble et al., 2005). Herein, we recognize the cytotoxic
Fig. 12. Lung tumor lysates from the various treatment groups (see Fig. 10) were analyzed by Western blot for (A) b-catenin, (B) c-Met, (C) EGFR and their expression
estimated using the ImageJ software (imagej.nih.gov/ij/download/). Protein expression of targets were normalized against b-actin for at least 3 replicate determination for
each treatment group and the results expressed as percentage of control lysate (set at 100%). One-way ANOVA followed by Dunnett’s test was used to compare differences
observed between control and treatment groups and Turkey’s test was used to compare differences between combination and single treatment groups. Signiﬁcant differences
(*P < 0.05 vs control and **P < 0.05 vs C-DIM-5, C-DIM-8 and doc single treatments) are indicated.
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late apoptosis in a concentration dependent manner. Together
with a concentration-dependent G0/G1 arrest of A549 cells,
C-DIM-5 and C-DIM-8 showed remarkable cytotoxic proﬁles. These
results were paralleled by inhibition of antiapoptotic survivin
mRNA and protein expression in tumors from mice treated with
C-DIM-5 and C-DIM-8 and was similar to observations reported
by Lee et al. (2009) in pancreatic cells. Consistent with FACS anal-
ysis, C-DIM-5 also induced the expression of the tumor suppressor
protein p21, an inhibitor of cell cycle progression (Lee et al., 2009).
Pre-formulation studies on the aqueous solubility and intestinal
permeability of C-DIM-5 and C-DIM-8 revealed that these com-
pounds were highly insoluble with low permeability. Thus, to en-
sure optimal concentration at the tumor microenvironment, the
inhalation route was exploited; our previous studies with a
PPARc-active C-DIM demonstrated the efﬁcacy of the inhalation
method for effective delivery (Ichite et al., 2009). To ensure
efﬁcient deposition in the lung for effective therapeutic effect,particles of aerosolized droplets with an effective cutoff diameter
of about 4 lm with an optimal range of 1–3 lm (Patlolla et al.,
2010) corresponding to particles collected on stage 5 of the viable
impactor are preferred. Hence, cytotoxicity studies of aerosol drop-
lets collected on this stage were used to predict effectiveness for
in vivo lung alveolar deposition; with both formulations registering
appreciable cytotoxic activities. We also characterized the aerody-
namic behavior of the aerosol particles using the eight-stage ACI by
estimating the MMAD and GSD with acceptable respirabilities of
aerosolized C-DIM-5 and C-DIM-8 being attained.
The metastatic mouse tumor model closely recapitulates the
advanced stages of tumor development (Boffa et al., 2004; Lee
et al., 2011b) and was chosen to study the anti-metastatic effects
of aerosolized C-DIM-5 and C-DIM-8. Physical examination of
resected lungs showed different lung morphologies with signiﬁ-
cant tumor nodule reduction in the treatment groups compared
to control. Histological staining (H&E) of lung sections displayed
highly disseminated cytoplasmic structures with less occurrence
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Absence of toxicity of treatment was supported by no change in
body or lung weight measurements over the treatment period.
However, signiﬁcant tumor regression was observed following
treatment with doc, C-DIM-5 and C-DIM-8 alone, and more pro-
nounced effects were observed for the combination of C-DIMs plus
doc. Importantly, the 0.440 mg/kg and 0.464 mg/kg lung deposition
doses of C-DIM-5 and C-DIM-8 respectively in nebulized formwere
6-fold more than their corresponding oral formulations which gave
comparable effects (Lee et al., 2011b). The antimetastatic activities
of C-DIM-5 and C-DIM-8 were evident in their inhibition of neo-
vascularization characterized by decreased VEGF and CD31 stain-
ing with optimum inhibition occurring in combination treatment
with doc which was consistent with TUNEL staining.
Although C-DIM-5 and C-DIM-8 differentially activate and inac-
tivate TR3-dependent transactivation respectively, both com-
pounds inhibit lung tumor growth, induce apoptosis, and inhibit
angiogenesis in vivo and also exhibit comparable effects in vitro.
However, these effects were not TR3-dependent as shown from
immunostaining and Western blot. Immunostaining for TR3 on
lung tumor tissues showed nuclear localization of TR3 and no sta-
tistical difference in the IHS score among all groups (Cho et al.,
2007; Lee et al., 2011a). The expression of TR3 following treatment
with C-DIM-5 and C-DIM-8 were unchanged compared to control.
The similarity in their anticancer activity was also observed in pan-
creatic cancer (Lee et al., 2010, 2009). Therefore, we further inves-
tigated differences between these compounds by investigating
genes and selected proteins in treated and control tumors. The pat-
tern of gene and protein expression was similar for C-DIM-5 and
C-DIM-8 with respect to induction or repression of genes associ-
ated with growth, survival, and angiogenesis; the only exceptions
were in the unique repression of Angpt1, Birc5, and Cdc25a by
C-DIM-5 and Atm by C-DIM-8. Previous studies on a series of
p-phenylsubstituted C-DIMs including C-DIM-5 and C-DIM-8 show
that all of these compounds induce endoplasmic recticulum (ER)
stress (Lei et al., 2008b) and ongoing studies suggest that this re-
sponse was TR3-dependent via the inactivation pathway. Thus,
we concluded that C-DIM-5 may also inactivate TR3 and it is also
possible that this compound may be metabolized in vivo to give
C-DIM-8 via the oxidative demethylation pathway to yield C-
DIM-8.
5. Conclusion
In summary, our study conﬁrms the efﬁcacy of the C-DIM ana-
logs as potent anticancer agents for treatment of metastatic lung
cancer. Our delivery of C-DIM-5 and C-DIM-8 in a metastatic
mouse lung tumor by inhalation enhanced multimodal therapeutic
effects without causing toxicity and resulted in signiﬁcant reduc-
tion in tumor growth compared to control tumor and a 6-fold efﬁ-
cacy over corresponding oral formulations (Lee et al., 2011a). Both
compounds exhibited anti-metastatic, antiangiogenic, and apopto-
tic activities by inﬂuencing the gene and protein expression of var-
ious mediators involved in these pathways. These results underpin
the usefulness of the C-DIM analogs as candidates for treating ad-
vanced stage lung cancer. Current studies are examining the effect
of these compounds in overcoming the multi-drug resistant phe-
notypic properties of cancer stem cells and their mechanisms asso-
ciated with C-DIM-TR3 interactions are also being investigated.
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